{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:53:44Z","timestamp":1787964824804,"version":"build-2784847793"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biopha.2018.11.032","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:42:27Z","timestamp":1543236147000},"page":"1593-1601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Metformin; an old antidiabetic drug with new potentials in bone disorders"],"prefix":"10.1016","volume":"109","author":[{"given":"Saman","family":"Bahrambeigi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-8986","authenticated-orcid":false,"given":"Vahid","family":"Shafiei-Irannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0005","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1210\/jc.2017-00042","article-title":"Type 2 diabetes and osteoporosis: a guide to optimal management","volume":"102","author":"Paschou","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2018.11.032_bib0010","first-page":"db141611","article-title":"Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by PPAR\u03b3 coactivator-1\u03b1 and skeletal muscle atrogenes: adiponectin receptor 1 as a potential target for reversing diabetes-induced osteopenia","author":"Khan","year":"2015","journal-title":"Diabetes."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11684-013-0243-9","article-title":"Impact of diabetes and its treatments on skeletal diseases","volume":"7","author":"Yan","year":"2013","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00198-014-2676-7","article-title":"Biochemical markers of bone turnover in diabetes patients\u2014a meta-analysis, and a methodological study on the effects of glucose on bone markers","volume":"25","author":"Starup-Linde","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0030","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1210\/jc.2012-1546","article-title":"Circulating osteogenic precursor cells in type 2 diabetes mellitus","volume":"97","author":"Manavalan","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.11.032_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11010-009-0344-6","article-title":"High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP\/protein kinase A\/extracellular signal-regulated kinase pathway","volume":"338","author":"Wang","year":"2010","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes. Care."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0045","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/cbdd.13013","article-title":"New insights into antidiabetic drugs: Possible applications in cancer treatment","volume":"90","author":"Shafiei-Irannejad","year":"2017","journal-title":"Chem. Biol. Drug. Des."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0050","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00125-017-4269-4","article-title":"Diabetes, bone and glucose-lowering agents: basic biology","volume":"60","author":"Lecka-Czernik","year":"2017","journal-title":"Diabetologia."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0055","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00125-017-4283-6","article-title":"Diabetes, bone and glucose-lowering agents: clinical outcomes","volume":"60","author":"Schwartz","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.biopha.2018.11.032_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0070","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","article-title":"Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation","volume":"146","author":"Ali","year":"2005","journal-title":"Endocrinology."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0075","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","article-title":"PPAR-\u03b3 regulates osteoclastogenesis in mice","volume":"13","author":"Wan","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1359\/jbmr.090732","article-title":"Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies","volume":"25","author":"Molinuevo","year":"2010","journal-title":"J J. Bone. Miner. Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.maturitas.2013.04.004","article-title":"Diabetes and bone health","volume":"76","author":"Antonopoulou","year":"2013","journal-title":"Maturitas."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0090","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cell.2015.05.029","article-title":"Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation","volume":"161","author":"Wei","year":"2015","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF03351073","article-title":"Osteoporosis and risk of fracture in patients with diabetes: an update","volume":"23","author":"Montagnani","year":"2011","journal-title":"Aging. Clin. Exp. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0100","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jbmr.5650110709","article-title":"Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia","volume":"11","author":"Katayama","year":"1996","journal-title":"J. Bone. Miner. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.V82260","article-title":"Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles","volume":"8","author":"Miyata","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jbmr.2106","article-title":"In vivo assessment of bone quality in postmenopausal women with type 2 diabetes","volume":"29","author":"Farr","year":"2014","journal-title":"J. Bone. Miner. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jbmr.1763","article-title":"Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures","volume":"28","author":"Patsch","year":"2013","journal-title":"J. Bone. Miner. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/03008200009067660","article-title":"Alterations of cartilage and collagen expression during fracture healing in experimental diabetes","volume":"41","author":"Gooch","year":"2000","journal-title":"Connect. Tissue. Res."},{"key":"10.1016\/j.biopha.2018.11.032_bib0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00003086-199411000-00032","article-title":"Type X collagen in fracture callus and the effects of experimental diabetes","volume":"308","author":"Topping","year":"1994","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0130","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1210\/jc.2008-2498","article-title":"Pentosidine and increased fracture risk in older adults with type 2 diabetes","volume":"94","author":"Schwartz","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.tem.2008.02.006","article-title":"Reciprocal regulation of bone and energy metabolism","volume":"19","author":"Lee","year":"2008","journal-title":"Trends. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00774-012-0367-z","article-title":"Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism","volume":"30","author":"Movahed","year":"2012","journal-title":"J. Bone. Miner. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1593","article-title":"Skeletal remodeling in health and disease","volume":"13","author":"Zaidi","year":"2007","journal-title":"Nature medicine"},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0155","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/endo.143.6.8834","article-title":"Divergent effects of selective peroxisome proliferator-activated receptor-\u03b32 ligands on adipocyte versus osteoblast differentiation","volume":"143","author":"Lecka-Czernik","year":"2002","journal-title":"Endocrinology."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0160","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/dom.12077","article-title":"Antidiabetic therapy effects on bone metabolism and fracture risk","volume":"15","author":"Montagnani","year":"2013","journal-title":"Diabetes. Obes. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/er.2009-0024","article-title":"From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis","volume":"31","author":"Manolagas","year":"2010","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11892-003-0051-8","article-title":"Osteoporosis and diabetes","volume":"3","author":"Chau","year":"2003","journal-title":"Curr. Diab. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrendo.2011.233","article-title":"Bone, sweet bone\u2014osteoporotic fractures in diabetes mellitus","volume":"8","author":"Hamann","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0168-8227(94)90126-0","article-title":"Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?","volume":"23","author":"Gregorio","year":"1994","journal-title":"Diabetes. Res. Clin. Pract."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0185","first-page":"2915","article-title":"Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover","volume":"82","author":"Okazaki","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","article-title":"Bone Loss and Bone Turnover in Diabetes","volume":"44","author":"Krakauer","year":"1995","journal-title":"Diabetes."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0195","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1007\/s00198-016-3689-1","article-title":"Visit-to-visit variation of fasting plasma glucose is a predictor of hip fracture in older persons with type 2 diabetes: the Taiwan Diabetes Study","volume":"27","author":"Chiang","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/8756-3282(93)90252-6","article-title":"Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus","volume":"14","author":"Wakasugi","year":"1993","journal-title":"Bone."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0205","first-page":"835","article-title":"The Risk of Hip Fractures in Older Individuals With Diabetes","volume":"30","author":"Lipscombe","year":"2007","journal-title":"A population-based study"},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF02509378","article-title":"Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus","volume":"58","author":"Munoz-Torres","year":"1996","journal-title":"Calcif. Tissue. Int."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s001980050082","article-title":"A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus","volume":"8","author":"Miazgowski","year":"1998","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.1590297","article-title":"Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients","volume":"159","author":"Jehle","year":"1998","journal-title":"J. Endocrinol."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0225","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/diacare.22.7.1196","article-title":"Bone mineral density in patients with type 1 and type 2 diabetes","volume":"22","author":"Tuominen","year":"1999","journal-title":"Diabetes. Care."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0230","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/1056-8727(95)00062-3","article-title":"Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus","volume":"10","author":"Sosa","year":"1996","journal-title":"J. Diabetes. Complications."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0235","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s001250051248","article-title":"Diabetes mellitus and the incidence of hip fracture: results from the Nord-Tr\u00f8ndelag Health Survey","volume":"42","author":"Fors\u00e9n","year":"1999","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0240","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM198009043031008","article-title":"Diabetes Mellitus and Risk of Skeletal Fracture","volume":"303","author":"Heath","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2796.1994.tb01284.x","article-title":"Hip and distal arm fracture rates in peri- and postmenopausal insulin-treated diabetic females","volume":"236","author":"Melchior","year":"1994","journal-title":"J. Intern. Med."},{"issue":"23","key":"10.1016\/j.biopha.2018.11.032_bib0250","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1001\/jama.1992.03490230063029","article-title":"Sex differences in osteoporosis in older adults with non\u2014insulin-dependent diabetes mellitus","volume":"268","author":"Barrett-Connor","year":"1992","journal-title":"JAMA."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0255","first-page":"1198","article-title":"Diabetes and Risk of Fracture","volume":"24","author":"Ivers","year":"2001","journal-title":"The Blue Mountains Eye Study"},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem.86.1.7139","article-title":"Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective Study","volume":"86","author":"Schwartz","year":"2001","journal-title":"T J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0265","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/03007990902801147","article-title":"Bone health in diabetes: considerations for clinical management","volume":"25","author":"Adami","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.biopha.2018.11.032_bib0270","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/oxfordjournals.aje.a116622","article-title":"Risk Factors for Hip Fracture in Middle-aged Norwegian Women and Men","volume":"137","author":"Meyer","year":"1993","journal-title":"Am. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0275","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2337\/diacare.24.7.1192","article-title":"Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women","volume":"24","author":"Nicodemus","year":"2001","journal-title":"Diabetes. Care."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0280","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00198-004-1625-2","article-title":"Risk factors for foot fracture among individuals aged 45 years and older","volume":"15","author":"Luetters","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002239900498","article-title":"Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus","volume":"63","author":"Rosato","year":"1998","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0290","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdiacomp.2011.02.004","article-title":"Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications","volume":"25","author":"Vi\u00e9gas","year":"2011","journal-title":"J. Diabetes. Complications."},{"issue":"1038","key":"10.1016\/j.biopha.2018.11.032_bib0295","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/pgmj.2010.146399rep","article-title":"Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype","volume":"88","author":"Berenbaum","year":"2012","journal-title":"Postgrad. Med. J."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0300","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/jc.2002-021394","article-title":"Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2","volume":"88","author":"Gunton","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0305","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/imj.12369","article-title":"Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?","volume":"44","author":"Huang","year":"2014","journal-title":"J. Intern. Med."},{"issue":"26","key":"10.1016\/j.biopha.2018.11.032_bib0310","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","article-title":"Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome","volume":"338","author":"Nestler","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0315","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/diab.41.3.354","article-title":"Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM","volume":"41","author":"Wid\u00e9n","year":"1992","journal-title":"Diabetes."},{"issue":"11","key":"10.1016\/j.biopha.2018.11.032_bib0320","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genomics."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0325","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00125-011-2407-y","article-title":"Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle","volume":"55","author":"Chopra","year":"2012","journal-title":"Diabetologia."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4093\/dmj.2013.37.1.1","article-title":"AMPK and exercise: glucose uptake and insulin sensitivity","volume":"37","author":"O\u2019Neill","year":"2013","journal-title":"Diabetes. Metab. J."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mce.2012.06.013","article-title":"Exercise-induced AMPK activity in skeletal muscle: role in glucose uptake and insulin sensitivity","volume":"366","author":"Friedrichsen","year":"2013","journal-title":"Mol. Cell. Endocr."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0340","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical Pharmacokinetics of Metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0345","first-page":"233","article-title":"Metformin: a review of its pharmacological properties and therapeutic use","volume":"5","author":"Hermann","year":"1979","journal-title":"Diabete. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/JOE-11-0306","article-title":"AMP-activated protein kinase pathway and bone metabolism","volume":"212","author":"Jeyabalan","year":"2012","journal-title":"J. Endocr."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1113\/jphysiol.2006.108944","article-title":"AMP-activated protein kinase \u2013 development of the energy sensor concept","volume":"574","author":"Hardie","year":"2006","journal-title":"J. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0360","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2006.05.006","article-title":"Expanding role of AMPK in endocrinology","volume":"17","author":"Kola","year":"2006","journal-title":"Trends. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0365","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.molmed.2008.09.007","article-title":"AMPK: a metabolic gauge regulating whole-body energy homeostasis","volume":"14","author":"Lage","year":"2008","journal-title":"Trends. Mol.Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0370","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in Health and Disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0375","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"28","key":"10.1016\/j.biopha.2018.11.032_bib0380","doi-asserted-by":"crossref","first-page":"25226","DOI":"10.1074\/jbc.M202489200","article-title":"The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways","volume":"277","author":"Fryer","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0385","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1152\/ajpendo.00453.2005","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues","volume":"291","author":"LeBrasseur","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"S4","key":"10.1016\/j.biopha.2018.11.032_bib0390","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/ijo.2008.124","article-title":"The regulation of AMP-activated protein kinase by upstream kinases","volume":"32","author":"Carling","year":"2008","journal-title":"Int. J. Obes."},{"issue":"22","key":"10.1016\/j.biopha.2018.11.032_bib0395","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.cub.2003.10.031","article-title":"LKB1 is the upstream kinase in the AMP-activated protein kinase cascade","volume":"13","author":"Woods","year":"2003","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0400","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1748-1716.2009.01977.x","article-title":"Structure and function of AMP\u2010activated protein kinase","volume":"196","author":"Oakhill","year":"2009","journal-title":"Acta. Physiol."},{"key":"10.1016\/j.biopha.2018.11.032_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2014.09.004","article-title":"AMPK: positive and negative regulation, and its role in whole-body energy homeostasis","volume":"33","author":"Hardie","year":"2015","journal-title":"Curr. Opin. Cell. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0410","doi-asserted-by":"crossref","first-page":"E411","DOI":"10.1152\/ajpendo.00317.2003","article-title":"5\u2032-AMP-activated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle","volume":"286","author":"Fr\u00f8sig","year":"2004","journal-title":"Am. J.. Physiol. Endocr. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0415","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1113\/jphysiol.2005.082669","article-title":"5\u2032 AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes","volume":"564","author":"Wojtaszewski","year":"2005","journal-title":"J. Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0420","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrm2249","article-title":"AMP-activated\/SNF1 protein kinases: conserved guardians of cellular energy","volume":"8","author":"Hardie","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0425","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1748-1716.2009.01975.x","article-title":"AMP\u2010activated protein kinase\u2013a sensor of glycogen as well as AMP and ATP?","volume":"196","author":"McBride","year":"2009","journal-title":"Acta. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0430","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1152\/jappl.1999.87.5.1990","article-title":"Chronic activation of 5\u2032-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle","volume":"87","author":"Holmes","year":"1999","journal-title":"J. Appl. Physiol."},{"issue":"25","key":"10.1016\/j.biopha.2018.11.032_bib0435","doi-asserted-by":"crossref","first-page":"15983","DOI":"10.1073\/pnas.252625599","article-title":"AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation","volume":"99","author":"Zong","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"27","key":"10.1016\/j.biopha.2018.11.032_bib0440","doi-asserted-by":"crossref","first-page":"23977","DOI":"10.1074\/jbc.C200171200","article-title":"AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling","volume":"277","author":"Bolster","year":"2002","journal-title":"J. Biol.Chem."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0445","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0450","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1113\/jphysiol.2006.108324","article-title":"AMPK and cell proliferation\u2013AMPK as a therapeutic target for atherosclerosis and cancer","volume":"574","author":"Motoshima","year":"2006","journal-title":"J. Physiol."},{"issue":"41","key":"10.1016\/j.biopha.2018.11.032_bib0455","doi-asserted-by":"crossref","first-page":"30107","DOI":"10.1074\/jbc.M705325200","article-title":"The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor","volume":"282","author":"Greer","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0460","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1042\/bst0301064","article-title":"Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase","volume":"30","author":"Hardie","year":"2002","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0465","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1042\/bst0311157","article-title":"Bypassing the glucose\/fatty acid cycle: AMP-activated protein kinase","volume":"31","author":"Carling","year":"2003","journal-title":"Biochem Soc Trans."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030048","article-title":"Roles of 5\u2032-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis","volume":"375","author":"Rutter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2018.11.032_bib0475","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/ijo.2008.116","article-title":"AMPK: a key regulator of energy balance in the single cell and the whole organism","volume":"32","author":"Hardie","year":"2008","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0480","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1152\/physiol.00044.2005","article-title":"AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle","volume":"21","author":"Hardie","year":"2006","journal-title":"Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2006.108506","article-title":"Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders","volume":"574","author":"Viollet","year":"2006","journal-title":"J. Physiol."},{"issue":"20","key":"10.1016\/j.biopha.2018.11.032_bib0490","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s00018-010-0454-z","article-title":"AMP-activated protein kinase and its downstream transcriptional pathways","volume":"67","author":"Cant\u00f3","year":"2010","journal-title":"Cell. Mol. Life. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0495","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.cellsig.2016.06.004","article-title":"AMPK promotes osteogenesis and inhibits adipogenesis through AMPK-Gfi1-OPN axis","volume":"28","author":"Wang","year":"2016","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0500","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1196\/annals.1402.034","article-title":"Suppression of PPAR Transactivation Switches Cell Fate of Bone Marrow Stem Cells from Adipocytes into Osteoblasts","volume":"1116","author":"Takada","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2018.11.032_bib0505","doi-asserted-by":"crossref","first-page":"14515","DOI":"10.1074\/jbc.M700030200","article-title":"Wnt Signaling Stimulates Osteoblastogenesis of Mesenchymal Precursors by Suppressing CCAAT\/Enhancer-binding Protein \u03b1 and Peroxisome Proliferator-activated Receptor \u03b3","volume":"282","author":"Kang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0510","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1210\/en.2006-1587","article-title":"Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone","volume":"148","author":"Lazarenko","year":"2007","journal-title":"Endocrinology."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0515","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2010.03.161","article-title":"AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of \u03b2-catenin at Ser 552","volume":"395","author":"Zhao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"29","key":"10.1016\/j.biopha.2018.11.032_bib0520","doi-asserted-by":"crossref","first-page":"12017","DOI":"10.1073\/pnas.0705070104","article-title":"AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1\u03b1","volume":"104","author":"J\u00e4ger","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0525","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0026-895X(25)09536-7","article-title":"Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells","volume":"50","author":"Gimble","year":"1996","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0530","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C","article-title":"CBFA1: A molecular switch in osteoblast biology","volume":"219","author":"Ducy","year":"2000","journal-title":"Dev. Dyn."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0535","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bone.2010.08.001","article-title":"AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts","volume":"47","author":"Lee","year":"2010","journal-title":"Bone."},{"issue":"6937","key":"10.1016\/j.biopha.2018.11.032_bib0540","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0545","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11745-009-3338-y","article-title":"Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol","volume":"44","author":"Oliaro\u2010Bosso","year":"2009","journal-title":"Lipids."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0550","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1601-0825.2005.01172.x","article-title":"Statins and bone metabolism","volume":"12","author":"Horiuchi","year":"2006","journal-title":"Oral. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0555","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0560","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis\u2010related fractures in the United States, 2005\u20132025","volume":"22","author":"Burge","year":"2007","journal-title":"J. Bone. Miner. Res."},{"issue":"5356","key":"10.1016\/j.biopha.2018.11.032_bib0565","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1126\/science.279.5356.1528","article-title":"Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors","volume":"279","author":"Ferrari","year":"1998","journal-title":"Science."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0570","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/ten.1998.4.415","article-title":"Chondrogenic Differentiation of Cultured Human Mesenchymal Stem Cells from Marrow","volume":"4","author":"Mackay","year":"1998","journal-title":"Tissue. Eng."},{"issue":"5411","key":"10.1016\/j.biopha.2018.11.032_bib0575","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage Potential of Adult Human Mesenchymal Stem Cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science."},{"issue":"5484","key":"10.1016\/j.biopha.2018.11.032_bib0580","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0585","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","article-title":"New bisphosphonates in the treatment of bone diseases","volume":"15","author":"Gatti","year":"1999","journal-title":"Drugs. Aging."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0590","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11914-015-0286-8","article-title":"Diabetes and its effect on bone and fracture healing","volume":"13","author":"Jiao","year":"2015","journal-title":"Curr. Osteoporos. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0595","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200308000-00004","article-title":"The pathophysiology of bone disease in gastrointestinal disease","volume":"15","author":"Bernstein","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0600","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","article-title":"Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression","volume":"375","author":"Kanazawa","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.11.032_bib0605","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2006.02.030","article-title":"Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture","volume":"536","author":"Cortizo","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0610","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12072-015-9649-6","article-title":"Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease","volume":"10","author":"Sofer","year":"2016","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0615","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jdiacomp.2009.05.002","article-title":"Metformin reverses the deleterious effects of high glucose on osteoblast function","volume":"24","author":"Zhen","year":"2010","journal-title":"J. Diabetes. Complications."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0620","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bone.2010.04.596","article-title":"AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass","volume":"47","author":"Shah","year":"2010","journal-title":"Bone."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0625","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1211\/jpp.60.12.0017","article-title":"Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells","volume":"60","author":"Gao","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"issue":"06","key":"10.1016\/j.biopha.2018.11.032_bib0630","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2007-992786","article-title":"Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells","volume":"116","author":"Schurman","year":"2008","journal-title":"Exp. Clin. Endocrinol. Diabetes."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0635","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bone.2010.12.003","article-title":"Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2","volume":"48","author":"Jang","year":"2011","journal-title":"Bone."},{"issue":"2014","key":"10.1016\/j.biopha.2018.11.032_bib0640","article-title":"Metformin rescues the MG63 osteoblasts against the effect of high glucose on proliferation","author":"Shao","year":"2014","journal-title":"J. Diabetes. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0645","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diabres.2013.05.016","article-title":"Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin","volume":"101","author":"Tolosa","year":"2013","journal-title":"Diabetes. Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0650","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcb.23206","article-title":"Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats","volume":"112","author":"Mai","year":"2011","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0655","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.joen.2012.03.010","article-title":"Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand\/osteoprotegerin","volume":"38","author":"Liu","year":"2012","journal-title":"J. Endod."},{"issue":"2016","key":"10.1016\/j.biopha.2018.11.032_bib0660","first-page":"4847812","article-title":"Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE\/NFkappaB Pathway Suppression","author":"Zhou","year":"2016","journal-title":"J. Diabetes. Res."},{"issue":"1-3","key":"10.1016\/j.biopha.2018.11.032_bib0665","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2010.02.051","article-title":"Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats","volume":"635","author":"Gao","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0670","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1902\/jop.2009.090414","article-title":"The effect of metformin on alveolar bone in ligature-induced periodontitis in rats: A pilot study","volume":"81","author":"Bak","year":"2010","journal-title":"J. Periodontol."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0675","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0680","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type 2 diabetes: update of a population\u2010based study","volume":"23","author":"Melton","year":"2008","journal-title":"J. Bone. Miner. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0685","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/jcb.26275","article-title":"Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: An in vitro study","volume":"119","author":"Qin","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0690","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00198-013-2371-0","article-title":"The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing","volume":"24","author":"Jeyabalan","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.biopha.2018.11.032_bib0695","series-title":"Principles and practice of pediatric oncology","author":"Pizzo","year":"2015"},{"issue":"S1","key":"10.1016\/j.biopha.2018.11.032_bib0700","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V","article-title":"Bone cancers","volume":"75","author":"Dorfman","year":"1995","journal-title":"Cancer."},{"key":"10.1016\/j.biopha.2018.11.032_bib0705","first-page":"1975","article-title":"Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, Cancer incidence and survival among children and adolescents","author":"Ries","year":"1999","journal-title":"United States SEER Program."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0710","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer."},{"issue":"14","key":"10.1016\/j.biopha.2018.11.032_bib0715","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1073\/pnas.84.14.5048","article-title":"Parathyroid hormone-related protein purified from a human lung cancer cell line","volume":"84","author":"Moseley","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0720","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0006-291X(87)90581-X","article-title":"N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains","volume":"146","author":"Stewart","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2018.11.032_bib0725","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer\u2013induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"5484","key":"10.1016\/j.biopha.2018.11.032_bib0730","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0735","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.biopha.2018.11.032_bib0740","first-page":"349","article-title":"Bone Disorders in Cancer, Osteoporosis Rehabilitation: A Practical Approach, Springer International Publishing","author":"Oleson","year":"2017","journal-title":"Cham"},{"issue":"25","key":"10.1016\/j.biopha.2018.11.032_bib0745","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Sahra","year":"2008","journal-title":"Oncogene."},{"issue":"24","key":"10.1016\/j.biopha.2018.11.032_bib0750","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3748\/wjg.v16.i24.3025","article-title":"Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma","volume":"16","author":"Donadon","year":"2010","journal-title":"World. J. Gastroenterol. WJG"},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0755","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.mehy.2013.08.032","article-title":"Inhibitory effect of metformin on bone metastasis of cancer via OPG\/RANKL\/RANK system","volume":"81","author":"Wang","year":"2013","journal-title":"Medical hypotheses"},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0760","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Antidiabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0765","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cbdd.13078","article-title":"Metformin enhances doxorubicin sensitivity via inhibition of doxorubicin efflux in P\u2010gp\u2010overexpressing MCF\u20107 cells","volume":"91","author":"Shafiei\u2010Irannejad","year":"2018","journal-title":"Chem. Biol. Drug. Des."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0770","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11095-018-2404-7","article-title":"Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly (lactide-co-glycolide)-d-\u03b1-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles","volume":"35","author":"Shafiei-Irannejad","year":"2018","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.biopha.2018.11.032_bib0775","doi-asserted-by":"crossref","first-page":"e3627","DOI":"10.1371\/journal.pone.0003627","article-title":"Osteoclasts are active in bone forming metastases of prostate cancer patients","volume":"3","author":"Roato","year":"2008","journal-title":"PLoS. One."},{"issue":"7130","key":"10.1016\/j.biopha.2018.11.032_bib0780","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1038\/nature05657","article-title":"Bone metastasis: can osteoclasts be excluded?","volume":"445","author":"Martin","year":"2007","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0785","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1007\/s13277-015-3751-1","article-title":"Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0790","doi-asserted-by":"crossref","first-page":"e83832","DOI":"10.1371\/journal.pone.0083832","article-title":"Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug","volume":"8","author":"Garofalo","year":"2013","journal-title":"PLoS. One."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0795","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3892\/or.2013.2862","article-title":"Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation","volume":"31","author":"Quattrini","year":"2014","journal-title":"Oncol Rep."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0800","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3892\/ijo.2017.3950","article-title":"Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2","volume":"50","author":"Shang","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0805","first-page":"7948","article-title":"Metformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt","volume":"15","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2018.11.032_bib0810","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1007\/s13277-015-4639-9","article-title":"LKB1\/AMPK inhibits TGF-\u03b21 production and the TGF-\u03b2 signaling pathway in breast cancer cells","volume":"37","author":"Li","year":"2016","journal-title":"Tumor. Biol."},{"key":"10.1016\/j.biopha.2018.11.032_bib0815","first-page":"2665","article-title":"Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies","volume":"35","author":"Bodmer","year":"2012","journal-title":"Diabetes. Care."},{"issue":"12","key":"10.1016\/j.biopha.2018.11.032_bib0820","doi-asserted-by":"crossref","DOI":"10.1593\/neo.131434","article-title":"Regulation of metformin response by breast cancer associated gene 2","volume":"15","author":"Buac","year":"2013","journal-title":"Neoplasia."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0825","first-page":"1617","article-title":"Metformin use and prostate cancer in Caucasian men: results from a population-based case\u2013control study","volume":"20","author":"Wright","year":"2009","journal-title":"Cancer. Causes. Control."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0830","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0835","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18773\/austprescr.2004.059","article-title":"Thiazolidinediones-mechanisms of action","volume":"27","author":"Greenfield","year":"2004","journal-title":"Aust. Prescr."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0840","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","article-title":"Bone is a target for the antidiabetic compound rosiglitazone","volume":"145","author":"Rzonca","year":"2004","journal-title":"Endocrinology."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0845","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7","article-title":"Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPAR\u03b32","volume":"74","author":"Lecka\u2010Czernik","year":"1999","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0850","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1210\/en.2006-1121","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo","volume":"148","author":"Lecka-Czernik","year":"2007","journal-title":"Endocrinology."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0855","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","article-title":"The peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial","volume":"92","author":"Grey","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0860","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.07.008","article-title":"Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat","volume":"38","author":"Lazarenko","year":"2006","journal-title":"Bone."},{"issue":"9","key":"10.1016\/j.biopha.2018.11.032_bib0865","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-2007-979837","article-title":"Mechanisms of the glycaemic effects of sulfonylureas","volume":"28","author":"Ashcroft","year":"1996","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.biopha.2018.11.032_bib0870","first-page":"12","article-title":"Clinical pharmacokinetics of sulfonylureas: a brief review","volume":"37","author":"Melander","year":"1983","journal-title":"Ann. Clin. Res."},{"issue":"7","key":"10.1016\/j.biopha.2018.11.032_bib0875","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI9017","article-title":"Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover","volume":"105","author":"Ogata","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2018.11.032_bib0880","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1083\/jcb.200204046","article-title":"Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts","volume":"159","author":"Akune","year":"2002","journal-title":"J. Cell. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2018.11.032_bib0885","first-page":"1194","article-title":"Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus","volume":"80","author":"Bouillon","year":"1995","journal-title":"J. Clin. Endocr. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2018.11.032_bib0890","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s001980070114","article-title":"Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study","volume":"11","author":"Pastor","year":"2000","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.biopha.2018.11.032_bib0895","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0091270006289850","article-title":"Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects","volume":"46","author":"Herman","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2018.11.032_bib0900","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures, A meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes. Care."},{"issue":"3","key":"10.1016\/j.biopha.2018.11.032_bib0905","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.141.3.7366","article-title":"Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors","volume":"141","author":"Bollag","year":"2000","journal-title":"Endocrinology."},{"issue":"2","key":"10.1016\/j.biopha.2018.11.032_bib0910","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1152\/ajpendo.00364.2006","article-title":"Effects of glucose-dependent insulinotropic peptide on osteoclast function","volume":"292","author":"Zhong","year":"2007","journal-title":"Am. J. Physiol. Endocr. Metab."},{"key":"10.1016\/j.biopha.2018.11.032_bib0915","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diabres.2016.04.029","article-title":"DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes \u2013 A systematic review and meta-analysis","volume":"116","author":"Mamza","year":"2016","journal-title":"Diabetes. Res. Clin. Pract."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218371130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218371130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:25:02Z","timestamp":1777875902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218371130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":183,"alternative-id":["S0753332218371130"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.11.032","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin; an old antidiabetic drug with new potentials in bone disorders","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}